Disseminated nocardiosis is a severe form of Nocardia infection in which the organism spreads beyond the initial site, requiring prompt and sustained antibiotic management. This page summarises the first-line clinical approach.
Clinical SituationDisseminated disease represents one of the most severe presentations of nocardiosis. Because infection may involve multiple organ systems simultaneously, the treatment strategy must account for both breadth of initial coverage and the durability of the response.
Treatment ApproachManagement begins with empiric combination antibiotic therapy, typically involving multiple agents selected for activity against Nocardia. As susceptibility data become available and clinical improvement is established, the regimen may be narrowed accordingly. Treatment for disseminated disease is prolonged.
Clinical GoalsThe primary markers of treatment success are signs of clinical improvement and a favourable radiographic response on follow-up chest imaging.
This is particularly crucial in severe forms of nocardiosis (eg, disseminated or progressive pulmonary infection), where 2 or 3 different agents are typically initiated empirically.
Antibiotics that most Nocardia isolates demonstrate susceptibility to include amikacin, imipenem, linezolid, and trimethoprim-sulfamethoxazole (TMP-SMX).
If combination therapy is started empirically, treatment can be narrowed to monotherapy, particularly if there are signs of clinical improvement.
TMP-SMX is the most well-studied and preferred agent for monotherapy.
Patients with localized pulmonary nocardiosis are traditionally treated for up to 6 months, while those with disseminated disease (particularly involving the CNS) are commonly treated for at least 12 months.
Patients with pulmonary or CNS disease should undergo follow-up chest or brain imaging, respectively, to evaluate for response to treatment.
DOI: 10.1093/cid/ciae643
View source ↗